Immuno-oncology and immunotherapy Part C

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Norma received her master’s degree in health biology from Paris Saclay. In 2013, she joined the laboratory of Dr. Guido Kroemer at the Centre de Recherche des Cordeliers (Paris, France) and at Gustave Roussy (Villejuif, France), the largest center for oncological patients in Europe. She worked on several projects linked to immunosurveillance, culminating with her obtaining her PhD in 2017 with an original work on “Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance”. She then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Galluzzi. Her current research is focused on investigating resistance to immunotherapy in a mouse model of HR+ breast cancer. Maud Charpentier received her M.Sc. in Cellular Biology and her Ph.D. in Immunology from the University of Nantes, France. She chose to pursue an academic career and continued her postdoctoral training in the United States. She joined the Department of Radiation Oncology at Weill Cornell Medicine under the mentorship of Dr. Sandra Demaria. Maud has a long-standing interest in the anti-tumor immune response and its role in controlling cancer progression and treatment outcomes. Her research focuses on understanding the synergy between radiation therapy and immunotherapy in solid tumors, with the aim of overcoming resistance to treatment and developing innovative therapeutic approaches in preclinical models.

1. Simplified acid extraction and quantification of histones in human tumor cells

Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, Rocío Flores-Campos; Juan Antonio Flores, Antonio Pérez-Pérez, Luis de la Cruz-Merino, Víctor Sánchez-Margalet and Nabil Hajji

2. Expression, purification and characterization of phosphatidylserine-targeting antibodies for biochemical and therapeutic applications

Varsha Gadiyar, David Calianese, Rachael Pulica, Christopher Varsanyi, Ziren Wang, Ahmed Aquib, Alok Choudhary and Raymond B. Birge

3. In vitro ILC differentiation from human HSCs

Silvia Santopolo, Cecilia Ciancaglini, Francesca Romana Mariotti, Lorenzo Moretta and Linda Quatrini

4. Optimizing protocols for human regulatory T cell isolation, expansion and functional characterization

Sánchez-Moreno Inés, Martín-Otal Celia, Lasarte Juan José and Lozano Teresa

5. (1)Specific selection of stimulation-responsive  T cells utilizing a short-term activation assay

Christian Peters, Jara Simeonov, Daniel Gombert and Dieter Kabelitz

6. Generation of human and murine exhausted CD8+ T cells in vitro

Rosa Ana Lacalle, Raquel Blanco, Rebeca García-Lucena and Santos Mañes

7. Ex vivo assessment of human neutrophil motility and migration

Noor A.M. Bakker, Claudia Burrello and Karin E. de Visser

8. Flow cytometry-based monitoring of myeloid-derived suppressor cells in the peripheral blood of patients with solid tumors

Anna-Jasmina Donaubauer, Ilka Scheer, Rainer Fietkau, Udo S. Gaipl, Benjamin Frey

9. Deciphering neutrophil heterogeneity in human blood and tumors: Methods for isolating neutrophils and assessing their effect on T-cell proliferation

Nicolas Delhez, Frank Aboubakar Nana, Camille Houbion, Alexandre Bayard, Annika Bruger, Christophe Vanhaver, Sven Brandau, Pierre van der Bruggen and Thibault Hirsch

10. Splenocytes antitumor cytotoxicity assessment after prophylactic vaccination or drug treatment of tumor-bearing mice

Kenny Misael Calvillo-Rodriguez, Ana Luisa Rivera-Lazarin, Reyes Tamez-Guerra, Ana Carolina Martinez-Torres and Cristina Rodriguez-Padilla

11. Therapeutic treatment of tumor-bearing mice with drug-killed cancer cells: A method to confirm immunogenic cell death and assess its therapeutic effectiveness

Kenny Misael Calvillo-Rodriguez, Maria Norma Gonzalez-Flores, Reyes Tamez-Guerra,Cristina Rodriguez-Padilla, Marilena Antunes-Ricardo and Ana Carolina Martinez-Torres

12. Single-cell RNA flow cytometry to assess intratumoral production of cytokines/chemokines

Khiem C. Lam and Romina S. Goldszmid

13. Multidimensional profiling of cancer microenvironments in FFPE tissues by imaging mass cytometry

Marieke E. Ijsselsteijn and Noel FCC de Miranda

14. Evaluation of lymphocyte infiltration into cancer spheroids by immunofluorescent staining and 3D imaging

Mireia Cruz De los Santos and Andreas Lundqvist

15. Quantitative pre-clinical imaging of hypoxia and vascularity using MRI and PET Georgia Kanli, Selma Boudissa, Radovan Jirik, Tom Adamsen, Heidi Espedal, Hans-Olav Rolfsnes, Frits Alan Thorsen, Jesus Pacheco Torres, Bassam Janji and Olivier Keunen

16. Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research

Sophia Stock, Luisa Fertig, Vivien D. Menkhoff, Thaddäus Strzalkowski, Manuel Caruso and Sebastian Kobold